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regulars  – conference  news
The Festschrift of Peter Sandercock
Given that Edinburgh is world-famous for its festivals (there are 12 in total), some might have considered it brave 
of the organisers of the Festschrift Conference 
in honour of Peter Sandercock to refer to the 
day as “a festival of epidemiology, clinical 
trials and evidence based medicine”. Their 
confidence was justified however, as over 170 
people from around the world came together 
on the 15th April 2016 to celebrate Peter’s 
career, his achievements and his contribution 
to stroke research.
The day began with a look to the past, and 
a reminder that 30 years ago, when Peter 
began his research, knowledge of global 
stroke epidemiology was limited and there 
were no effective evidence-based treatments 
for stroke. Stefano Ricci spoke about Peter’s 
work with the Oxford Community Stroke 
Project (working as Charles Warlow’s first 
research fellow), and its influence on our 
understanding of the epidemiology of stroke 
as well as its role in introducing a practicable 
yet simple method of stroke classification. 
Bo Norrving discussed the changing global 
burden of stroke, and in particular how it is 
declining in high yet increasing in low income 
countries. Peter Langhorne colourfully likened 
the work of the Cochrane Stroke Group in 
looking through “long-dead clinical trials”, to 
haruspicy, the ancient practice of predicting 
the future by looking through the entrails of 
dead animals. On a more positive note, he 
went on to discuss the beneficial influence the 
group (for whom Peter served as coordinating 
editor for a decade), has had on stroke prac-
tice worldwide. Zhengming Chen completed 
the session by reflecting on IST-1 and CAST, 
the first mega-trials testing treatments for acute 
stroke, and how they revolutionised a field 
that was previously lacking in high quality 
evidence. 
The next session was entitled ‘from past to 
present’ focusing on aspects of current large 
scale trials in stroke and trauma in which 
Peter is involved.  Colin Baigent discussed 
Peter’s role as co-chief investigator of the 
IST-3 trial, which, with over 3000 patients, 
accounts for around half of the total avail-
able randomised evidence on the effect of 
thrombolysis in acute stroke. Next Ian Roberts 
spoke about the three CRASH trials in trauma 
and head injury, in which Peter has played a 
supporting role.  He made a nice point that 
while the ‘how to’ of designing trials is well 
understood,   the ‘how to’ of actually running 
these  large trials is a ‘craft’ which is passed 
from ‘master craftsman’ to ‘apprentice’. Martin 
Dennis spoke about the portfolio of trials he 
has run (Peter in a supporting role again) 
establishing the evidence behind interventions 
that may protect the rest of the body whilst 
the brain has time to recover after a stroke. 
Richard Lindley concluded the session with 
a talk on the nuances behind conducting 
stroke trials in low and middle income coun-
tries, and how interventions may need to 
be adapted to a given population based on 
affordability. Paradoxically, he also said, some 
low-cost interventions evaluated in low-in-
come countries may well find application in 
the developed world too!
The session after lunch was centred on the 
future of stroke research, and Joanna Wardlaw 
began by discussing the process of translating 
an interesting clinical observation, through 
basic science and into clinical trials, using 
small vessel disease as an exemplar. Prof 
Wardlaw identified the ‘Sandercock tool box’ 
– a list of tips to advancing medical knowledge 
using Peter’s pragmatic approach to science. 
Next up was Rustam Al-Shahi Salman who 
used the example of haemorrhagic stroke to 
discuss how randomised control trials need 
to be big, simple, and easy to do in order to 
be successful. He also explained the import-
ance of understanding the local population 
in conducting an international trial (even if 
that means camel riding in Mongolia). Gillian 
Mead discussed the potential role of fluoxetine 
in recovery after stroke, and how conducting 
several concurrent ‘sister’ trials can be a 
useful alternative to a single multi-national 
trial; in this case, the FOCUS (UK), EFFECTS 
(Scandinavia) and AFFINITY (Australia) trials. 
Will Whiteley completed the look into the 
future with a talk on the potential value of 
using ‘big data’ to improve stroke care, and the 
possibilities of incorporating machine-learning 
technology into medical research. 
In the final session of the day Shaun 
Treweek spoke about Trial Forge (www.trial-
forge.org), an initiative that intends to improve 
the evidence base behind the process of 
conducting trials and Jane Armitage discussed 
the need to train a new generation of experts 
in clinical trials, reinforcing the importance of 
apprenticeship in learning this trade. 
Appropriately, Peter gave the last lecture of 
the day. He spoke about the highs and lows of 
his career, in what he referred to as “36 years 
of team science”. His top tip for success? “You 
need to be steely in a nice way”.
There were recurrent themes over the 
course of the conference when speakers 
expressed their opinions of Peter and his 
approach towards his work and his colleagues. 
“Calm” and “diplomatic” were the two most 
frequently used adjectives throughout the 
day. Many cited his diplomacy as the crucial 
factor in holding these mega-trials together. 
Several speakers regarded Peter as a “master 
craftsman” in clinical trials. However, Craig 
Anderson, from Sydney, in a typically robust 
antipodean fashion, characterised Peter 
(with a twinkle in his eye as he said it) as a 
“tenacious bastard”. Much laughter ensued. 
The most evident aspect of the day was how 
Peter’s approach to research has influenced 
many stroke physicians, trialists and epidemi-
ologists. In all it was an enlightening, enjoyable 
day that covered the entire spectrum of stroke 
research whilst celebrating the role Peter has 
played during his illustrious 36-year career in 
the field. 
Congratulations and happy retirement to 
Prof Sandercock. Edinburgh can proudly add 
a 13th festival to its events of 2016.
Conference details: 15 April 2016, Edinburgh, Scotland. Report by: Tim Wilkinson, MBChB(hons), BMed Sci(hons), MSc MRCP(Edin), Clinical Research Fellow in 
Neurology, Centre for Clinical Brain Sciences, University of Edinburgh. Conflict of interest statement: The author declares that there are no conflicts of interest.
ACNR > VOLUME 16 NUMBER 2 > AUG-OCT 2016 > 27
